Nektar Therapeutics (NKTR) and Editas Medicine Inc. (NASDAQ:EDIT) Comparing side by side

Nektar Therapeutics (NASDAQ:NKTR) and Editas Medicine Inc. (NASDAQ:EDIT) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nektar Therapeutics 19 1.05 174.14M 3.52 8.08
Editas Medicine Inc. 23 0.00 48.82M -2.27 0.00

Demonstrates Nektar Therapeutics and Editas Medicine Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Nektar Therapeutics 928,746,666.67% 37.6% 29.7%
Editas Medicine Inc. 212,908,853.03% -47.6% -27.4%

Volatility & Risk

Nektar Therapeutics has a beta of 2.63 and its 163.00% more volatile than Standard and Poor’s 500. Editas Medicine Inc. has a 2.51 beta and it is 151.00% more volatile than Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Nektar Therapeutics are 14.9 and 14.8 respectively. Its competitor Editas Medicine Inc.’s Current Ratio is 8.5 and its Quick Ratio is 8.5. Nektar Therapeutics can pay off short and long-term obligations better than Editas Medicine Inc.

Analyst Recommendations

The Recommendations and Ratings for Nektar Therapeutics and Editas Medicine Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Nektar Therapeutics 1 4 3 2.38
Editas Medicine Inc. 0 0 0 0.00

Nektar Therapeutics’s upside potential currently stands at 32.41% and an $26.88 consensus target price.

Insider & Institutional Ownership

Roughly 94.8% of Nektar Therapeutics shares are held by institutional investors while 78.9% of Editas Medicine Inc. are owned by institutional investors. Insiders held 0.6% of Nektar Therapeutics shares. Comparatively, 3.98% are Editas Medicine Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Nektar Therapeutics -11.39% -20.57% -10.05% -33.97% -44.23% -13.42%
Editas Medicine Inc. -2.88% 4.17% 8.74% 18.66% -14.14% 10.99%

For the past year Nektar Therapeutics has -13.42% weaker performance while Editas Medicine Inc. has 10.99% stronger performance.

Summary

Nektar Therapeutics beats on 10 of the 12 factors Editas Medicine Inc.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The companyÂ’s drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). It has a research collaboration agreement with Takeda Pharmaceutical Company Limited to explore the anti-cancer activity of NKTR-214; and a strategic collaboration with Eli Lilly and Company to develop and commercialize NKTR-358. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.

Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. It is developing a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and collaboration, option, and license agreement with Adverum Biotechnologies, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.